Parsortix platform to support minimally invasive analysis across various cancer trials

Data suggests microbiome co-therapy may help overcome resistance to anti‑PD‑1 treatment

Belfast base will expand regulatory support, boost innovation and deepen engagement

Responders achieved weight loss and improvements in physical function

Enfortumab vedotin and pembrolizumab recommended for NHS Scotland

Second national grant strengthens company’s expanding global IP estate

Early safety and efficacy signals support move into repeat‑dose phase 2a trial

Partnership builds on existing collaboration and adds two new UCB‑nominated projects

Nihr‑funded phase 2 study to assess progesterone delivery using Callavid device